BRPI1011453A2 - formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina - Google Patents

formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina

Info

Publication number
BRPI1011453A2
BRPI1011453A2 BRPI1011453A BRPI1011453A BRPI1011453A2 BR PI1011453 A2 BRPI1011453 A2 BR PI1011453A2 BR PI1011453 A BRPI1011453 A BR PI1011453A BR PI1011453 A BRPI1011453 A BR PI1011453A BR PI1011453 A2 BRPI1011453 A2 BR PI1011453A2
Authority
BR
Brazil
Prior art keywords
formulation
drug
dosage form
asenapine hemipamoate
hemipamoate salt
Prior art date
Application number
BRPI1011453A
Other languages
English (en)
Inventor
Gerardus Johannes Kemperman
Johannes Antonius Hendrikus Van Laarjoven
Werenfridus Adrianus Faassen
Original Assignee
Msd Oss Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Oss Bv filed Critical Msd Oss Bv
Publication of BRPI1011453A2 publication Critical patent/BRPI1011453A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI1011453A 2009-06-24 2010-06-24 formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina BRPI1011453A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22002709P 2009-06-24 2009-06-24
PCT/EP2010/058960 WO2010149727A2 (en) 2009-06-24 2010-06-24 Injectable formulations containing asenapine and method of treatment using same

Publications (1)

Publication Number Publication Date
BRPI1011453A2 true BRPI1011453A2 (pt) 2016-03-15

Family

ID=43386952

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011453A BRPI1011453A2 (pt) 2009-06-24 2010-06-24 formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina

Country Status (13)

Country Link
US (2) US8658687B2 (pt)
EP (1) EP2453870A2 (pt)
JP (1) JP5801295B2 (pt)
KR (1) KR101435296B1 (pt)
CN (1) CN102596172A (pt)
AR (1) AR077225A1 (pt)
AU (1) AU2010264670A1 (pt)
BR (1) BRPI1011453A2 (pt)
CA (1) CA2766291C (pt)
MX (1) MX2012000061A (pt)
RU (1) RU2012102247A (pt)
TW (1) TW201113018A (pt)
WO (1) WO2010149727A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524921A1 (en) * 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
EP2524920A1 (en) * 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
TWI552751B (zh) 2011-06-20 2016-10-11 H 朗德貝克公司 投予4-((1r,3s)-6-氯-3-苯基-二氫茚-1-基)-1,2,2-三甲基-哌及其鹽用於治療精神分裂症的方法
US10022445B2 (en) * 2012-07-26 2018-07-17 Hisamitsu Pharmaceutical Co., Inc. Patch
WO2014068372A1 (en) * 2012-11-01 2014-05-08 Torrent Pharmaceuticals Ltd Pharmaceutical composition of tapentadol for parenteral administration
FR3020810B1 (fr) * 2014-05-06 2016-05-06 Servier Lab Nouveau sel de l'ivabradine et son procede de preparation.
WO2016198113A1 (en) 2015-06-11 2016-12-15 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
RS67063B1 (sr) * 2017-01-09 2025-08-29 Relmada Therapeutics Inc Injektabilne suspenzije
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
ES2970570T3 (es) * 2017-11-07 2024-05-29 Intervet Int Bv Composiciones farmacéuticas inyectables de isoxazolina y su uso contra una infestación por parásitos
KR102694519B1 (ko) * 2017-11-07 2024-08-13 인터벳 인터내셔널 비.브이. 큰 크기의 이속사졸린 입자를 제조하는 방법
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US20230355612A1 (en) * 2020-08-26 2023-11-09 Shanghai Bocimed Pharmaceutical Co., Ltd. Pharmaceutically acceptable salt of cariprazine and crystal form thereof, and preparation method therefor and use thereof
WO2023160583A1 (zh) * 2022-02-22 2023-08-31 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation
EP0569096A1 (en) 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
HK1008417A1 (en) 1994-03-02 1999-05-07 Merck Sharp & Dohme B.V. Sublingual or buccal pharmaceutical composition
WO1998054186A1 (en) * 1997-05-26 1998-12-03 Akzo Nobel N.V. Salts of aromatic sulphonic acids
US6169084B1 (en) 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
AU2005293552B2 (en) * 2004-10-15 2011-04-14 Msd Oss B.V. Treatment of bipolar disorders and associated symptoms
EP1710245B1 (en) * 2005-04-07 2007-08-22 N.V. Organon Crystal form of asenapine maleate
DK1710241T3 (da) * 2005-04-07 2010-03-01 Organon Nv Intermediatforbindelser til fremstilling af trans-5-chlor-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol
TW200817414A (en) * 2006-07-05 2008-04-16 Organon Nv Process for the preparation of asenapine and intermediate products used in said process
ATE527266T1 (de) 2008-01-04 2011-10-15 Organon Nv Herstellungsverfahren für asenapin und in diesem verfahren verwendete zwischenprodukte

Also Published As

Publication number Publication date
TW201113018A (en) 2011-04-16
CA2766291A1 (en) 2010-12-29
WO2010149727A3 (en) 2011-04-21
KR20120030561A (ko) 2012-03-28
JP2012530759A (ja) 2012-12-06
US8658687B2 (en) 2014-02-25
CN102596172A (zh) 2012-07-18
MX2012000061A (es) 2012-06-01
US20120237561A1 (en) 2012-09-20
RU2012102247A (ru) 2013-07-27
AU2010264670A1 (en) 2012-01-19
WO2010149727A2 (en) 2010-12-29
EP2453870A2 (en) 2012-05-23
CA2766291C (en) 2016-06-21
JP5801295B2 (ja) 2015-10-28
KR101435296B1 (ko) 2014-08-27
US20140154322A1 (en) 2014-06-05
AR077225A1 (es) 2011-08-10

Similar Documents

Publication Publication Date Title
BRPI1011453A2 (pt) formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina
NL301291I2 (nl) sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301248I2 (nl) atogepant of een farmaceutisch aanvaardbaar zout daarvan
NL301157I2 (nl) odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl) Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301035I1 (nl) upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
BRPI0906467A2 (pt) forma de dose farmacêutica
NL300901I2 (nl) pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
SMT201500209B (it) Forme di dosaggio farmaceutiche a rilascio controllato
IL245328A0 (en) Pharmaceutical composition
IL229409B (en) Intranasal pharmaceutical dosage forms comprising naloxone
ZA201304709B (en) A pharmaceutical dosage form
BR112015003376A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
BR112012011902A2 (pt) cápsula farmacêutica
IL219276A0 (en) Gastroretentive dosage forms of poorly soluble drugs
BRPI1012246A2 (pt) composição farmacêutica contendo um fármaco e sirna
DK2652652T3 (da) Medikmentadministration
EP2568979A4 (en) RATIOMETRIC COMBINATORY MEDICINE ADMINISTRATION
SI2582366T1 (sl) Farmacevtska kombinacija za zdravljenje bolečine
IL231622B (en) Pharmaceutical composition for treatment of cachexia
BRPI1005433A2 (pt) preparações farmacêuticas transdérmicas
BRPI0922653A2 (pt) preparação farmacêutica
DK2437736T3 (da) Lægemiddelindgivelsessystemer
PT2665471T (pt) Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg
BR112012031102A2 (pt) forma de dosagem oral sólida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]